We analyze the earnings along side the following peers of Emergent BioSolutions Inc. – SIGA Technologies, Inc., PharmAthene, Inc., Merck & Co., Inc., XOMA Corporation, Chimerix, Inc., Celgene Corporation, Celldex Therapeutics, Inc., GlaxoSmithKline plc Sponsored ADR, Pfizer Inc. and Teva Pharmaceutical Industries Limited Sponsored ADR (SIGAQ-US, PIP-US, MRK-US, XOMA-US, CMRX-US, CELG-US, CLDX-US, GSK-US, PFE-US and TEVA-US) that have also reported for this period.
Summary numbers: Revenues of USD 126.11 million, Net Earnings of USD 14.10 million, and Earnings per Share (EPS) of USD 0.32.
Gross margins widened from 68.72% to 78.38% compared to the same quarter last year, operating (EBITDA) margins now 23.32% from 14.79%.
Year-on-year change in operating cash flow of -76.86% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Emergent Biosolutions Inc (NYSE:EBS) stock is currently trading 9.09% below its 52-week-high, 70.43% above its 52-week-low. The 1-year stock price history is in the range of $19.31 – $36.2. Emergent BiosolutionsInc (EBS) has a price to earnings ratio of 34.1 versus Healthcare sector average of 53.82. EBS stock price has outperformed the S&P 500 by 27.2%. The Biotechnology company is currently valued at $1.28 billion and its share price closed the last trading session at $32.91. The stock has a 50-day moving average of $33.67 and a 200-day moving average of $31.49.
Emergent BiosolutionsInc (EBS) current short interest stands at 3.41 million shares. It has decreased by 1% from the same period of last month. Around 11% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.37 million shares, the number of days required to cover the short positions stand at 9.3 days.
EBS reported last quarter earnings on August 06. The Biotechnology company announced earnings per share of $0.36 against a consensus Street estimate of $0.16, beating the average estimate by $0.2. This corresponds to an increase of $0.5 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently three analysts that cover Emergent BiosolutionsInc stock. Of those three, three have a Buy rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $41.
In term of ownership, company insiders have sold 0.5% of their stock over the last six months while institutions have increased their positions by 7.17%. As a whole, institutions own 75.4% of the total outstanding shares.
Emergent Biosolutions, Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The Company produces a vaccine for anthrax.